The Value of a Biomarker Should be Judged on What it Adds to the Clinical Assessment: Not the Area Under the Curve
- PMID: 38095530
- DOI: 10.1097/CCM.0000000000006035
The Value of a Biomarker Should be Judged on What it Adds to the Clinical Assessment: Not the Area Under the Curve
Comment on
-
Reliability of Admission Procalcitonin Testing for Capturing Bacteremia Across the Sepsis Spectrum: Real-World Utilization and Performance Characteristics, 65 U.S. Hospitals, 2008-2017.Crit Care Med. 2023 Nov 1;51(11):1527-1537. doi: 10.1097/CCM.0000000000005968. Epub 2023 Jul 3. Crit Care Med. 2023. PMID: 37395622
References
-
- Lawandi A, Oshiro M, Warner S, et al.: Reliability of admission procalcitonin testing for capturing bacteremia across the sepsis spectrum: Real-world utilization and performance characteristics, 65 U.S. hospitals, 2008-2017. Crit Care Med. 2023; 51:1527–1537
-
- Vogeli A, Ghasemi M, Gregoriano C, et al.: Diagnostic and prognostic value of the D-dimer test in emergency department patients: Secondary analysis of an observational study. Clin Chem Lab Med. 2019; 57:1730–1736
-
- Wyss G, Berger S, Haubitz S, et al.: The Shapiro-Procalcitonin algorithm (SPA) as a decision tool for blood culture sampling: Validation in a prospective cohort study. Infection. 2020; 48:523–533
-
- Shapiro NI, Wolfe RE, Wright SB, et al.: Who needs a blood culture? A prospectively derived and validated prediction rule. J Emerg Med. 2008; 35:255–264
-
- Laukemann S, Kasper N, Kulkarni P, et al.: Can we reduce negative blood cultures with clinical scores and blood markers? Results from an observational cohort study. Medicine (Baltim). 2015; 94:e2264
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
